Literature DB >> 24523242

Focal adhesion kinase (FAK) siRNA inhibits human hypertrophic scar by suppressing integrin α, TGF-β and α-SMA.

Rui Chen1, Zhiliang Zhang, Zhujia Xue, Lin Wang, Mingang Fu, Yi Lu, Ling Bai, Dongqing Zhang, Zhihong Fan.   

Abstract

The effect of focal adhesion kinase (FAK) on suppressing scarring and the potential molecular mechanism underlying it has been investigated. Ten samples of human hypertrophic scars (HS) tissue cultured in vitro were transfected with FAK siRNA mediated by liposome. Quantitative real-time PCR was used to detect the expression of integrin α, transforming growth factor-β (TGF-β), FAK and α-smooth muscle actin (α-SMA) after transfection. MTT assay was used as a measure of fibroblast proliferation. Flow cytometry and (3)H-proincorporation technique gave measurements of the cell cycle and the quantity of collagen synthesis, respectively. Expression of FAK was effectively blocked, accompanied by decreasing expression of integrin α, TGF-β and α-SMA in hypertrophic scars fibroblast (HSFB) cells. One to 4 h after transfection with FAK siRNA, proliferation of HSFB cells was strongly inhibited (P < 0.01), reaching a maximum at 48 h. The proportion of G1 cells was higher and the proportion of the S and G2 cells lower after transfection. The amount of collagen synthesis in HSFB cells decreased when HSFB cells were transfected for 48 h. RNA interference targeting the FAK gene can block the two abnormal signal transduction pathways mediated by the integrin and TGF-β receptors that are responsible for hyperplasia and contracture of the scar, making FAK iRNA therapy a potentially effective approach in HS treatment.
© 2014 International Federation for Cell Biology.

Entities:  

Keywords:  focal adhesion kinase (FAK); hypertrophic scars (HS); integrin α; transforming growth factor-β1 (TGF-β); α-smooth muscle actin (α-SMA)

Mesh:

Substances:

Year:  2014        PMID: 24523242     DOI: 10.1002/cbin.10265

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  9 in total

1.  Back Grafting the Split-Thickness Skin Graft Donor Site.

Authors:  Jeremy Goverman; Casey T Kraft; Shawn Fagan; Benjamin Levi
Journal:  J Burn Care Res       Date:  2017 Jan/Feb       Impact factor: 1.845

Review 2.  Current progress in understanding the molecular pathogenesis of burn scar contracture.

Authors:  Jianglin Tan; Jun Wu
Journal:  Burns Trauma       Date:  2017-05-22

3.  miR-495 inhibits the growth of fibroblasts in hypertrophic scars.

Authors:  Bingyu Guo; Qiang Hui; Zhishan Xu; Peng Chang; Kai Tao
Journal:  Aging (Albany NY)       Date:  2019-05-14       Impact factor: 5.682

4.  Apigenin inhibits growth and migration of fibroblasts by suppressing FAK signaling.

Authors:  Hongyi Wang; Bingyu Guo; Shixiu Lin; Peng Chang; Kai Tao
Journal:  Aging (Albany NY)       Date:  2019-06-05       Impact factor: 5.682

5.  Targeted apoptosis of myofibroblasts by elesclomol inhibits hypertrophic scar formation.

Authors:  Yi Feng; Jun-Jie Wu; Zi-Li Sun; Si-Yu Liu; Ming-Li Zou; Zheng-Dong Yuan; Shun Yu; Guo-Zhong Lv; Feng-Lai Yuan
Journal:  EBioMedicine       Date:  2020-04-03       Impact factor: 8.143

6.  FAK Inhibition Attenuates Corneal Fibroblast Differentiation In Vitro.

Authors:  Vincent Yeung; Sriniwas Sriram; Jennifer A Tran; Xiaoqing Guo; Audrey E K Hutcheon; James D Zieske; Dimitrios Karamichos; Joseph B Ciolino
Journal:  Biomolecules       Date:  2021-11-12

Review 7.  Emerging roles of focal adhesion kinase in cancer.

Authors:  Yu-Ling Tai; Lih-Chyang Chen; Tang-Long Shen
Journal:  Biomed Res Int       Date:  2015-03-31       Impact factor: 3.411

8.  Simultaneous deactivation of FAK and Src improves the pathology of hypertrophic scar.

Authors:  Linlin Su; Xiaodong Li; Xue Wu; Bo Hui; Shichao Han; Jianxin Gao; Yan Li; Jihong Shi; Huayu Zhu; Bin Zhao; Dahai Hu
Journal:  Sci Rep       Date:  2016-05-16       Impact factor: 4.379

9.  Expression correlation attenuates within and between key signaling pathways in chronic kidney disease.

Authors:  Hui Yu; Danqian Chen; Olufunmilola Oyebamiji; Ying-Yong Zhao; Yan Guo
Journal:  BMC Med Genomics       Date:  2020-09-21       Impact factor: 3.063

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.